Personalis Puts Independence At Approximately $525 Million In New Equity As It Defends Tempus Sale

The board preferred Tempus’s $16.25 deal to a higher verbal bid, citing delays, financing needs and risks to vaccine revenue.

Share
Personalis Puts Independence At Approximately $525 Million In New Equity As It Defends Tempus Sale

Personalis, which provides cancer genomic testing, argued Thursday that staying independent would require approximately $525 million in new equity as it defended its pending sale to Tempus. In an SEC merger presentation, the board made the case for accepting $16.25 per share despite a rival’s final verbal offer of $17.00.

The Cost Of Staying Independent

The funding estimate puts shareholder dilution at the center of the board’s argument. Management projects approximately $300 million in cumulative operating losses from the second half of 2026 through 2029, with about $16 million in cash left at year-end 2028 without future equity offerings.

Personalis reported $69.6 million in revenue for 2025 and used $74.9 million in operating cash that year. It had $211 million in net cash as of June 30, 2026, and reported second-quarter revenue of $22.4 million.

The company said raising the additional equity would erode existing holders’ ownership. Management also warned that clinical research spending is difficult to trim: smaller or narrower trials directly affect the probability of success.

Personalis’s tests help physicians find residual or returning cancer, track treatment response and select therapies. Pharmaceutical customers use its services in research and clinical trials. Its NeXT Personal Dx cancer-monitoring test depends on Tempus as its primary U.S. commercial channel.

That relationship began in November 2023. Tempus expanded the collaboration with a minority investment in August 2024. Personalis said its current testing economics are unfavorable, competitors are narrowing its technological lead, and cash needs could be substantially higher if the Tempus relationship ended or changed.

Why $17.00 Lost To $16.25

The board’s choice turns on what a higher bid might ultimately deliver. The bidder identified as Party A ended with a $17.00 verbal proposal requiring significant additional diligence. Personalis also anticipated a longer antitrust review and said the bidder required a waiver of another commercial counterparty’s change-of-control protection before signing.

The board assigned Party A’s offer values of $15.65, $14.45 and $13.30 per share under scenarios involving six, 12 and 18 months of additional closing time relative to Tempus. Those figures account for delay, but exclude the possibility of regulators blocking the deal or imposing remedies unacceptable to the bidder.

Party A had earlier described a potential path to $18.00–$20.75 per share. Party B withdrew on July 10, 2026, saying it could not offer a meaningful premium to the market price. Party C and Merck declined to pursue purchases; Merck, a shareholder with approximately 13%, signed an agreement supporting the Tempus merger.

Tempus raised its price indication four times, from $9.00 to $16.25. Personalis rejected phased purchase structures and a proposal containing contingent payment before obtaining the final terms. The board approved the merger in July.

For comparison, Centerview’s discounted-cash-flow assessment of the standalone plan ranged from $11.05 to $16.75 per share. TD Cowen’s range was $10.56 to $12.65. These assessments estimate the present value of projected future cash flows.

Shareholder lawyers are questioning the deal. Bleichmar Fonti & Auld said it is investigating the price and potential fiduciary-duty breaches. Halper Sadeh announced a merger investigation Wednesday.

Vaccine Success Was Already Assumed

Personalis said its independent valuation already included commercial success for Moderna and Merck’s personalized cancer vaccine, intismeran autogene. Management assigned the collaboration revenue a 100% probability before the August release of late-stage trial data.

That forecast assumes 210,000 samples in 2034 at approximately $1,000 per test. Growth from 2030 onward depends on approvals in additional cancer indications and global expansion. The board said Tempus’s offer exceeded the value of the standalone plan even with those assumptions.

The vaccine opportunity also carries a contractual risk. Personalis and Moderna extended their collaboration in December 2024, but the agreement allows Moderna to license Personalis technology and perform or outsource equivalent services under specified conditions and payments.

Tempus announced an expanded collaboration with Moderna and Merck on October 7, 2026, to support potential vaccine commercialization. Its responsibilities include collecting and transferring tissue and blood samples, with sequencing services subject to applicable regulatory approvals. Personalis said it does not retain explicit future rights as a commercial partner for the vaccine.

Protection Has A Lower Limit

Tempus, a healthcare technology company providing diagnostics and data services, can elect to pay up to 50% of the purchase consideration in cash. At least half would therefore be Tempus stock, giving Personalis holders exposure to the combined business after closing.

The stock-price protection fixes the offer’s value at $16.25 per Personalis share when the specified Tempus price measure exceeds $48.42. At or below that threshold, the exchange ratio is fixed at 0.3356, so the value of the stock consideration can decline.

Personalis may terminate if the specified Tempus price measure falls below $46.00 at closing. The measure generally uses a 15-trading-day volume-weighted average before closing.

The board repeatedly requested a two-way price protection mechanism that would preserve pre-closing stock-price upside. Tempus refused. Personalis said it prioritized the deal’s value and likelihood of completion over that uncertain upside.

Personalis holders face a choice between a pending cash-and-stock sale with defined downside limits and an independent plan management says requires approximately $525 million in fresh equity.

Sources

More on Personalis

All Personalis (PSNL) coverage →